ClinicalTrials.gg
CompletedNCT05386758Updated Jan 28, 2025Results posted

A Study to Evaluate Molnupiravir (MK-4482; MOV) in Participants With Severe Renal Impairment (MK-4482-003)

A Phase 1 interventional study of Molnupiravir in Renal Impairment, sponsored by Merck Sharp & Dohme LLC. Completed at 4 sites in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 32 studies in Renal Insufficiency by Merck & Co., Inc — 2 open to participants now, 2 under way, none of them phase 3. Renal Insufficiency · Merck & Co., Inc.

Enrollment
27th of 32
16 · median 26
Started
2022
with 1 other
Phase 1
25 of 32
2 open now
Registered
26th of 32
by date

Among the 32 studies in Renal Insufficiency by Merck & Co., Inc, this one is the 27th largest by enrollment, is one of 2 that started in 2022, is one of 25 in phase 1, and was the 26th registered.

Renal Insufficiency

1,413 studies on the registry are indexed under Renal Insufficiency; 146 are open to participants now.

Browse Renal Insufficiency studies →

Open to participants now

2 of the 32 studies in Renal Insufficiency by Merck & Co., Inc are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

Where they have run

Who these studies take

Of the 92 Renal Insufficiency studies recruiting now, 48 (52%) set no upper age limit and 19 (21%) stop at 75 or younger; 8 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 32 studies in Renal Insufficiency by Merck & Co., Inc, or all of them as a file.
02

Study summary

This purpose of this study is to evaluate the plasma pharmacokinetics (PK) of N-hydroxycytidine (NHC), the nucleoside metabolite of molnupiravir, after a single oral dose of 800 mg molnupiravir in participants with severe renal impairment compared to healthy mean matched control participants. This study will also assess the safety and tolerability of molnupiravir in participants with severe renal impairment and the urinary excretion of NHC after a single oral dose of 800 mg molnupiravir in participants with severe renal impairment compared to healthy mean matched control participants. The primary hypothesis is that the plasma PK participants with severe renal impairment will be similar to that observed in the healthy mean matched control participants.

03

Conditions studied

  • Renal Impairment

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The key Inclusion Criteria include but are not limited to the following:

  • (BMI) ≥18.5 kg/m\^2 and ≤35 kg/m\^2
  • Healthy participants: Baseline estimated (eGFR) ≥90 mL/min based on the 2021 Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) Creatinine equation
  • Severe renal impairment participants: Baseline estimated glomerular filtration rate (eGFR) \<30 mL/min based on the 2021 CKD-EPI Creatinine equation

Exclusion criteria

Exclusion Criteria:

The key Exclusion Criteria include but are not limited to the following:

  • Positive for surface antigen (HBsAg), antibodies or (HIV)
  • History of major surgery, donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks prior to the prestudy (screening) visit

Severe renal impairment participants:

  • History or presence of renal artery stenosis
  • Had a renal transplant
  • Currently taking medications to treat chronic medical conditions associated with renal disease if participant has not been on a stable regimen for at least 1 month and/or is unable to withhold the use of medication(s) within 4 hours prior to and 8 hours after administration of the study drug
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Panel A - Severe Renal Impairment Group

    Participants with severe renal impairment will receive a single oral 800 mg dose of molnupiravir.

    Drug: Molnupiravir

  • Experimental
    Panel B - Healthy Control Group

    Participants in the healthy mean matched control group will receive a single oral 800 mg dose of molnupiravir.

    Drug: Molnupiravir

Interventions

  • Four 200 mg capsules administered orally as a single dose

    Also known as: MK-4482; MOV; EIDD-2801

06

What researchers measure

Primary outcomes

  1. Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC)

    Blood for plasma samples was collected at pre-specified time points to determine the AUC0-inf of NHC.

    Time frame: Predose, 0.5,1.5, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose

  2. Maximum Plasma Concentration (Cmax) of NHC

    Blood for plasma samples was collected at pre-specified time points to determine the Cmax of NHC.

    Time frame: Predose, 0.5,1.5, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose

  3. Number of Participants Who Experienced an Adverse Event (AE)

    An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

    Time frame: Up to Day 15

Secondary outcomes

  1. Amount of Dose Administered Excreted in Urine (Ae) of N-hydroxycytidine (NHC)

    Urine was collected at pre-specified time points to determine the amount of dose Administered excreted in urine (Ae) of NHC.

    Time frame: Predose, 4, 8, 12 and 24 hours postdose

  2. Fraction of the Dose Administered Excreted in Urine (Fe) of NHC

    Urine was collected at pre-specified time points to determine the Fraction of the dose administered excreted in urine (Fe) of NHC.

    Time frame: Predose, 4, 8, 12 and 24 hours postdose

  3. Renal Clearance (CLr) of NHC

    Urine will be collected at pre-specified time points to determine the Renal Clearance (CLr) of NHC

    Time frame: Predose, 4, 8, 12 and 24 hours postdose

07

Results

Posted Jul 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Started88
Completed88
Not completed00

Outcome measures

PrimaryArea Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC)

Blood for plasma samples was collected at pre-specified time points to determine the AUC0-inf of NHC.

Time frame:
Predose, 0.5,1.5, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Geometric mean · hr*ng/mL
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC)
hr*ng/mLParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Area Under the Curve From Time 0 to Infinity (AUC0-inf) of N-hydroxycytidine (NHC)11100 (7990 to 15400)8960 (7660 to 10500)
Statistical analysis
  • Participants With Severe Renal Impairment vs Healthy Participants With Normal Renal Function · Gemetric mean ratio (gmr): 1.24 · 90% CI 0.94 to 1.64
PrimaryMaximum Plasma Concentration (Cmax) of NHC

Blood for plasma samples was collected at pre-specified time points to determine the Cmax of NHC.

Time frame:
Predose, 0.5,1.5, 2, 4, 6, 8, 12, 24, 48 and 72 hours postdose
Reported as:
Geometric mean · ng/mL
Maximum Plasma Concentration (Cmax) of NHC
ng/mLParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Maximum Plasma Concentration (Cmax) of NHC3920 (2810 to 5460)3240 (2630 to 4000)
Statistical analysis
  • Participants With Severe Renal Impairment vs Healthy Participants With Normal Renal Function · Geometric mean ratio (gmr): 1.21 · 90% CI 0.90 to 1.62
PrimaryNumber of Participants Who Experienced an Adverse Event (AE)

An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. An AE was therefore any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a study intervention. The number of participants who experienced an AE were reported.

Time frame:
Up to Day 15
Reported as:
Number · Participants
Number of Participants Who Experienced an Adverse Event (AE)
ParticipantsParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Number of Participants Who Experienced an Adverse Event (AE)20
SecondaryAmount of Dose Administered Excreted in Urine (Ae) of N-hydroxycytidine (NHC)

Urine was collected at pre-specified time points to determine the amount of dose Administered excreted in urine (Ae) of NHC.

Time frame:
Predose, 4, 8, 12 and 24 hours postdose
Reported as:
Geometric mean · mg
Amount of Dose Administered Excreted in Urine (Ae) of N-hydroxycytidine (NHC)
mgParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Amount of Dose Administered Excreted in Urine (Ae) of N-hydroxycytidine (NHC)3.72 ± 50.914.6 ± 172
SecondaryFraction of the Dose Administered Excreted in Urine (Fe) of NHC

Urine was collected at pre-specified time points to determine the Fraction of the dose administered excreted in urine (Fe) of NHC.

Time frame:
Predose, 4, 8, 12 and 24 hours postdose
Reported as:
Geometric mean · % of administered dose
Fraction of the Dose Administered Excreted in Urine (Fe) of NHC
% of administered doseParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Fraction of the Dose Administered Excreted in Urine (Fe) of NHC0.591 ± 50.92.33 ± 172
SecondaryRenal Clearance (CLr) of NHC

Urine will be collected at pre-specified time points to determine the Renal Clearance (CLr) of NHC

Time frame:
Predose, 4, 8, 12 and 24 hours postdose
Reported as:
Geometric mean · L/hr
Renal Clearance (CLr) of NHC
L/hrParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
Renal Clearance (CLr) of NHC0.338 ± 62.11.64 ± 162

Adverse events

Collected over Up to ~ Day 15. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Participants With Severe Renal Impairment0/8 (0%)0/8 (0%)2/8 (25%)
Healthy Participants With Normal Renal Function0/8 (0%)0/8 (0%)0/8 (0%)
Most frequent other events
Most frequent other events
EventParticipants With Severe Renal ImpairmentHealthy Participants With Normal Renal Function
ConstipationGastrointestinal disorders1/80/8
HyperkalaemiaMetabolism and nutrition disorders1/80/8

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Participants With Severe Renal ImpairmentHealthy Participants With Normal Renal FunctionTotal
Mean63.5 ± 7.959.6 ± 2.061.6 ± 5.9
Sex: Female, Male
Sex: Female, Male(Participants)Participants With Severe Renal ImpairmentHealthy Participants With Normal Renal FunctionTotal
Female011
Male8715
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Participants With Severe Renal ImpairmentHealthy Participants With Normal Renal FunctionTotal
Hispanic or Latino448
Not Hispanic or Latino448
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Participants With Severe Renal ImpairmentHealthy Participants With Normal Renal FunctionTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American235
White6511
More than one race000
Unknown or Not Reported000
08

Study locations

4 sites
  • Velocity Clinical Research, Hallandale Beach ( Site 0005)
    Hallandale Beach, Florida 33009, United States
  • Advanced Pharma CR, LLC ( Site 0004)
    Miami, Florida 33147, United States
  • Genesis Clinical Research, LLC ( Site 0003)
    Tampa, Florida 33603, United States
  • Thomas Jefferson University-Pharmacology, Physiology and Cancer Biology ( Site 0001)
    Philadelphia, Pennsylvania 19107, United States
09

References and documents

Publications

  • Duncan KE, Carstens RP, Butterfield KL, Jin Y, Inbody LR, Schaeffer AK, Matthews CZ, Zhao T, Patel S, Maas BM, Cheng MH, Stoch SA. Assessment of pharmacokinetics and tolerability following single-dose administration of molnupiravir in participants with hepatic or renal impairment. Clin Transl Sci. 2024 Dec;17(12):e70073. doi: 10.1111/cts.70073. PubMed 39601078 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · engagezone.msd.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2022 to primary completion in Feb 2023, 7 months.

Results were first posted in Jul 2024, 1 year 5 months after primary completion.

Of 213 industry-sponsored phase 1 interventional studies under Renal Insufficiency, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 7 months is below that.

Counting every sponsor, half of 231 studies reached it within 8 months; a quarter within 5 and three quarters within 16.

How these figures are worked out, and which studies are left out of them.

Registered
May 18, 2022
First posted
May 23, 2022
StartActual
Jun 29, 2022
Primary completionActual
Feb 4, 2023
CompletionActual
Mar 1, 2023
Results first posted
Jul 5, 2024
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05386758
Responsible party
Sponsor
First posted
May 23, 2022
Start date
Jun 29, 2022
Primary completion
Feb 4, 2023
Completion
Mar 1, 2023
Results posted
Jul 5, 2024
Last update
Jan 28, 2025

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Molnupiravir

Start the discussion